Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and letrozole in breast cancer, sponsored by Asan Medical Center. Primary endpoint: pathologic Complete Response. Started Sep 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Letrozole + Lapatinib
Single experimental group receiving combination therapy
03
Who it enrols
Postmenopausal women with ER-positive and HER2-positive invasive breast cancer (tumor > 2cm) and no prior treatment.
04
Endpoints
Primary
pathologic Complete Response
Secondary
Standardized Uptake Value
Beyond the preview
Go deeper on NCT01275859.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275859.